.START 

Praxis Biologics Inc. and American Cyanamid Co. said the Federal Trade Commission granted their request for early termination of the waiting period for mergers, clearing the way for Praxis to be acquired by American Cyanamid. 

Praxis, a Rochester, N.Y., developer and marketer of vaccines, said it scheduled a special shareholders meeting to consider the proposal on Nov. 14. 

As reported, American Cyanamid, of Wayne, N.J., agreed in principle to acquire Praxis in an exchange of securities valued at about $237 million.
American Cyanamid is a biotechnology and chemicals concern. 

